Insider and Congress filings

CRISPR Therapeutics AG (CRSP)

Biotechnology, listed on NASDAQ.

66 insider transactionslast filed Oct 20, 2026

Share
Download on the App StoreGet it on Google Play

Free on iOS and Android

Scan to get
the app

EarningsQ3 FY2026 · reported Nov 2, 2026

CRISPR Therapeutics AG missed by 14.1% on revenue.

Revenue $12.7M against a $14.8M consensus. EPS was -$1.15 a share under GAAP; the -$1.04 consensus is for adjusted EPS.

Revenue

Reported$12.7M
Consensus$14.8M

Beat 2Miss 4

EPS against the consensus, quarter by quarter. Outlined: a GAAP figure against an adjusted consensus.

Next report Feb 11, 2027. Consensus -$1.17 a share.

Every quarter

Money managers13F filings for Jun 30, 2026

524

institutions reported CRISPR Therapeutics AG shares in 13F filings for Jun 30, 2026. ARK Investment Management LLC held the largest stake, $516.0M.

The largest holders

BlackRock, Inc.$455.4M
Orbis Allan Gray Ltd$297.2M
Every holder

Insider tradesForm 4 · 10 open-market filings shown

10 open-market sales, 3 of them under 10b5‑1 plans.

Mar 23, 2026Oct 19, 2026

SalesSales under a plan

3 of 10 under a plan

A median 1 business day from trade to filing. Form 4 is due within two.

Every filing

CongressSTOCK Act disclosures to the House and Senate

3 Congress disclosures shown, from 2 members.

29dMedian delayof the 45 day limit
2 buys · 1 sellPurchases and sales in the disclosures shown
Every Congress trade in CRSPEvery disclosure
Companyfrom the company's filings and listing, as of Nov 12, 2026

About CRISPR Therapeutics AG

Exchange
NASDAQ
Sector
Healthcare
Industry
Biotechnology
Chief executive
Samarth Kulkarni
Employees
393
Listed since
Oct 19, 2016
Market value
$4.2B
Price to earnings (12 mo)
-
Net income per share, as reported (12 mo)
-$4.72
Dividend yield
-

www.crisprtx.com

GetSignal News3 articles · newest first

GetSignal News

HeadlineSourceDate
CRISPR Therapeutics presents Phase 1b CTX310 data at AHA 2026A single-course treatment with CTX310 produced mean reductions from baseline of 65% in ANGPTL3 and 63% in triglycerides at Day 30 in patients with severe hypertriglyceridemia.Company releaseNov 9, 2026
CRISPR Therapeutics appoints Siva Sakhamuri as chief technical officerSakhamuri's appointment took effect immediately on the day the company announced it, November 2, 2026.Company releaseNov 2, 2026
CRISPR Therapeutics CFO Raju Prasad to step downThe company said Prasad is leaving to pursue external opportunities, and the announcement was made October 19, 2026.Company releaseOct 19, 2026

Written by GetSignal with AI from SEC filings and the company's own press releases; each article links to its source. Not investment advice.

Company news from every company we cover

Earnings6 reported quarters · next on Feb 11, 2027

Earnings

QuarterEPSEPS expectedRevenueRevenue expectedResult
Q3 FY2026reported Nov 2, 2026-$1.15-$1.04$12.7M$14.8MEPS miss, GAAPRevenue miss
Q2 FY2026reported Aug 3, 2026-$0.94-$1.19$10.2M$7.4MEPS beat, GAAPRevenue beat
Q1 FY2026reported May 4, 2026-$1.28-$1.19$1.5M$6.1MEPS miss, GAAPRevenue miss
Q4 FY2025reported Feb 12, 2026-$1.37-$1.15$864K$4.7MEPS missRevenue miss
Q3 FY2025reported Nov 10, 2025-$1.17-$1.26$889K$9.1MEPS beat, GAAPRevenue miss
Q2 FY2025reported Aug 5, 2025-$2.40-$1.47$892K$6.1MEPS miss, GAAPRevenue miss

Actual against the consensus estimate at the time. A flag marks a beat or a miss of more than 1.5% either way; inside that band the quarter is in line. A flag marked GAAP compares a GAAP figure the company reported with an adjusted consensus, two different measures, so a one-time gain or charge can move it either way. A flag reads n/a only when a number is missing. Quarterly EPS is the figure set against the consensus, usually adjusted, so the quarters need not add up to the 12-month net income per share above. An estimate is a forecast made by analysts, not a company target.

No earnings call briefs on CRSP yet. Briefs from every company we cover.

Analysts

Analyst ratings and price targets

Past year Each firm's latest target, newest first

Each firm's latest price target on CRSP, newest first
FirmRatingTargetActionDate
Piper SandlerOverweight$110Target set
Wells FargoEqual Weight$70Cut from $75
UBSNeutral$52Initiated
Goldman SachsNeutral$55Target set
H.C. WainwrightBuy$80Target set
Morgan StanleyEqualweight$60Target set
BernsteinMarket Perform$56Target set
Evercore ISINot stated$76Raised from $74
ChardanBuy$76Raised from $74
NeedhamBuy$82Target set

Each firm's latest target from the past year, with the rating stated with its note or within three days of it. These are the firms' own views, not GetSignal's, and we do not endorse them. Not investment advice.

3 other firms rated CRSP in the past year with no current target listed here. Ratings and targets come from licensed market data providers. A target is listed only after its firm and company are confirmed against a report of the note. As of Nov 12, 2026.

13F filings13F positions as of Jun 30, 2026

Institutional holders

HolderValueSharesShares vs prior qtr% of shares out
ARK Investment Management LLCCathie Wood$516.0M9,460,939-16.4%9.80%
BlackRock, Inc.$455.4M8,348,977+8.7%8.65%
Orbis Allan Gray Ltd$297.2M5,449,161-10.8%5.65%
Capital World Investors$259.0M4,749,525+0.5%4.92%
State Street Corp$235.7M4,321,666+8.5%4.50%
GSK PLC$175.7M3,220,6270.0%3.34%
Geode Capital Management, LLC$136.9M2,509,915+5.6%2.60%
T. Rowe Price Investment Management, Inc.$112.0M2,053,017-30.5%2.13%
SR One Capital Management, LP$111.2M2,038,7630.0%2.11%
Two Sigma Investments, LP$108.5M1,988,621+34.1%2.06%
FMR LLC$104.1M1,908,503-2.4%1.98%
Sumitomo Mitsui Trust Group, Inc.$93.8M1,720,734-7.2%1.78%

A 13F reports long US equity positions and is filed within 45 days of the quarter end, so these are positions as they stood on Jun 30, 2026. For a manager's whole book see the fund directory. What a 13F covers and leaves out is explained in our guide to Form 13F.

Form 410 filings shown · newest filing first

Open-market insider trades

InsiderActionSharesPriceValueTrade dateDelay
(business days)
Samarth KulkarniChief Executive OfficerSold47,837$49.78$2.4MOct 19, 2026filed Oct 20, 20261d
Simeon GeorgeDirectorSold · scheduled14,514$49.63$720KOct 14, 2026filed Oct 16, 20262d
Samarth KulkarniChief Executive OfficerSold4,098$49.26$202KOct 14, 2026filed Oct 15, 20261d
James R. KasingerGeneral Counsel and SecretarySold1,040$49.26$51KOct 14, 2026filed Oct 15, 20261d
James R. KasingerGeneral Counsel and SecretarySold · scheduled1,990$60.04$119KOct 6, 2026filed Oct 8, 20262d
James R. KasingerGeneral Counsel and SecretarySold · scheduled10,400$60.24$626KSep 22, 2026filed Sep 24, 20262d
Ali BehbahaniDirectorSold13,679$57.09$781KSep 17, 2026filed Sep 21, 20262d
Naimish PatelChief Medical OfficerSold3,786$55.62$211KMay 29, 2026filed Jun 1, 20261d
Samarth KulkarniChief Executive OfficerSold10,020$46.78$469KMar 23, 2026filed Mar 24, 20261d
James R. KasingerGeneral Counsel and SecretarySold3,182$46.78$149KMar 23, 2026filed Mar 24, 20261d

One row is one filing, newest filing first. A filing that reported its trade in several tranches is summed, priced at the weighted average, and marked with its line count. Scheduled: set up in advance under a Rule 10b5-1 trading plan. The delay counts business days from the trade to the filing, the unit of Form 4's two business day deadline: weekends and federal holidays are skipped. How the filing itself works is explained in our guide to Form 4.

Other Form 4 activity (20)
InsiderEventSharesDate
Sivakesava SakhamuriChief Technical OfficerStock award130,000Nov 4, 2026
James R. KasingerGeneral Counsel and SecretaryStock award27,000Oct 26, 2026
Andrew Jacob SilverChief Financial OfficerStock award27,000Oct 26, 2026
Naimish PatelChief Medical OfficerStock award36,000Oct 26, 2026
Samarth KulkarniChief Executive OfficerStock award86,250Oct 26, 2026
Andrew Jacob SilverChief Financial OfficerStock award25,000Oct 19, 2026
Andrew Jacob SilverChief Financial OfficerOther Form 4 entry (see filing)95,374Oct 19, 2026
Samarth KulkarniChief Executive OfficerOption exercise100,000Oct 16, 2026
Simeon GeorgeDirectorOption exercise30,000Oct 14, 2026
Samarth KulkarniChief Executive OfficerOption exercise8,333Oct 13, 2026
James R. KasingerGeneral Counsel and SecretaryOption exercise2,113Oct 13, 2026
James R. KasingerGeneral Counsel and SecretaryOption exercise1,990Oct 6, 2026
James R. KasingerGeneral Counsel and SecretaryOption exercise10,400Sep 22, 2026
Ali BehbahaniDirectorOption exercise30,000Sep 17, 2026
Ali BehbahaniDirectorOther (see filing)75Aug 6, 2025
Raju PrasadChief Financial OfficerGift750Aug 7, 2026
Douglas A. TrecoDirectorStock award13,000Jun 5, 2026
Christian RommelDirectorStock award13,000Jun 5, 2026
Briggs MorrisonDirectorStock award13,000Jun 5, 2026
Sandesh MahatmeDirectorStock award13,000Jun 5, 2026

Awards, option exercises, shares withheld to cover tax and gifts all file on the same form as a purchase or a sale. None of them is a decision to trade, so they sit here rather than beside the ones that are.

STOCK Act3 disclosures · median 29d of the 45 allowed

Congress trades in CRSP

Since the trade: the stock's move from its estimated entry price (a purchase) or estimated exit price (a sale) to its current price, the latest close we hold. Not the member's result.

MemberTypeActionAmount disclosedSince the tradeTrade dateDisclosedDelay
Thomas R. SuozziStockSale$50,001 - $100,000-60.7% since the saleEstimated exit price $116.47, close on Mon Sep 20, 2021Current price $45.75, close on Wed Nov 11Sep 20, 2021Oct 5, 202115d
Thomas R. SuozziStockPurchase$50,001 - $100,000-58.3% since the tradeEstimated entry price $109.83, close on Thu Jun 3, 2021Current price $45.75, close on Wed Nov 11Jun 3, 2021Sep 23, 2021112d
Marjorie Taylor GreeneJointStockPurchase$1,001 - $15,000-75.3% since the tradeEstimated entry price $185.10, close on Thu Jan 21, 2021Current price $45.75, close on Wed Nov 11Jan 21, 2021Feb 19, 202129d

Estimated prices are the stock's closing price on the trade date. A disclosure gives a value band, not the price paid. Not investment advice. After a sale a positive figure means the stock kept rising after it.

A delay above 45 days is the gap between the dates on the report; we mark a filing late only after checking it.

Every Congress trade in CRSP filterable by party, chamber, type and account.

A congressional disclosure names a company by its ticker symbol alone, and a symbol can be reassigned after its previous holder leaves the market. One disclosure filed under CRSP is dated before this company began trading under it, and is not shown here.

Congress rows disclose a value range rather than an exact amount, and the STOCK Act allows up to 45 days to report. Full sourcing and the limits of this data are on the methodology page. A filing is a record of a transaction, not a signal, and nothing here is investment advice.

On Form 4, code P is an open-market purchase and S an open-market sale; a sale marked scheduled was set up in advance under a Rule 10b5-1 plan. Awards, option exercises, tax withholding and gifts (A, M, F and G) are listed under Other Form 4 activity and never counted as either.

A STOCK Act disclosure gives each trade as a band of dollar values, which we do not narrow, and is due within 45 days of the trade. An option is described by its underlying company's name; its row says it is an option.

Data as of Nov 12, 2026.

Methodology · Guide to Form 4 · Guide to the STOCK Act

Questions

What the filings on CRSP show and how current they are.

Are insiders buying or selling CRSP?

Across the 10 most recent open-market filings shown here, 0 were purchases and 10 were sales. 3 were scheduled in advance under a Rule 10b5-1 plan.

Which members of Congress have traded CRSP?

Thomas R. Suozzi and Marjorie Taylor Greene disclosed CRSP transactions in the filings shown here.

How quickly are CRSP trades disclosed?

Insider filings on this page reached the public a median of 1 business day after the transaction (weekends and federal holidays skipped), against the two business days Form 4 allows. Congressional disclosures took a median of 29 days, against the 45 the STOCK Act allows.

Related companies

traded by the same members

See every company we track